Trial Profile
A Multi-center Observational Study of Bevacizumab Plus 5-FU Based Chemotherapy as First Line and Second Line Treatment for Chinese Patients With Metastatic Colorectal Cancer (ML25391)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Roche
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 23 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.